What were the main outcomes of Regeneron's 2012 Annual Meeting of Shareholders?

The main outcomes reported in this 8-K filing were the election of five Class III directors and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor for the fiscal year ending December 31, 2012. Both proposals received strong shareholder approval.

How did shareholders vote on the election of directors?

Shareholders overwhelmingly elected all five nominees for Class III director positions. The 'Votes For' ranged from approximately 91.7 million to 98.3 million, indicating significant shareholder support for the proposed slate of directors.

Was the selection of the independent auditor approved by shareholders?

Yes, the proposal to ratify the appointment of PricewaterhouseCoopers LLP as Regeneron's independent registered public accounting firm for the fiscal year 2012 was approved by a substantial majority of the votes cast.

What are 'Broker Non-Votes' and why are they mentioned?

Broker Non-Votes occur when a broker holding shares in 'street name' for a beneficial owner does not vote on a particular proposal because they have not received voting instructions from the beneficial owner. They are reported to provide a complete picture of the voting results and are particularly common for non-routine matters. In this filing, they were noted for the director elections.

REGN 8-K: Shareholder Matters

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 14, 2012, detailing the outcomes of its Annual Meeting of Shareholders held on June 8, 2012. The primary purpose of the filing was to report on shareholder votes regarding the election of directors and the ratification of the company's independent registered public accounting firm. These votes are routine but important for corporate governance and financial oversight, providing insight into shareholder confidence in the board and the company's financial reporting.

Key Highlights

1Shareholders overwhelmingly approved the election of five Class III directors: Charles A. Baker, Michael S. Brown, M.D., Arthur F. Ryan, George L. Sing, and Marc Tessier-Lavigne, Ph.D., each elected to serve until the 2015 Annual Meeting.
2The appointment of PricewaterhouseCoopers LLP as Regeneron's independent registered public accounting firm for the fiscal year ending December 31, 2012, was ratified by shareholders.
3The election of directors saw strong support, with the lowest 'Votes For' count being over 91.7 million for Arthur F. Ryan, indicating broad shareholder confidence in the nominated individuals.
4The ratification of PricewaterhouseCoopers LLP received substantial approval, with over 104.8 million votes in favor, demonstrating shareholder trust in the firm's auditing capabilities.
5Broker non-votes were reported for director elections, a common occurrence where brokers do not have discretionary voting authority for certain proposals without specific instructions from the beneficial owner.
6The filing confirms the company's adherence to corporate governance best practices by holding an annual shareholder meeting and presenting key decisions for shareholder vote.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 14, 2012)

Summary

Key Highlights

Frequently Asked Questions